Identification and Characterization of a Novel Class of c-Jun N-terminal Kinase InhibitorsIgor A. Schepetkin, Mark T. Quinn|Molecular Pharmacology|2012Cited by 87
Further studies on 2-arylacetamide pyridazin-3(2H)-ones: Design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonistsMaria Paola Giovannoni, Mark T. Quinn, Аndrei I. Khlebnikov et al.|European Journal of Medicinal Chemistry|2013Cited by 49
Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1Аndrei I. Khlebnikov, Mark T. Quinn, Igor A. Schepetkin et al.|Journal of Molecular Modeling|2011Cited by 19
Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 InhibitorsIgor A. Schepetkin, Mark T. Quinn|Molecules|2023Cited by 13
Neuroprotective Effects of the Lithium Salt of a Novel JNK Inhibitor in an Animal Model of Cerebral Ischemia–ReperfusionIgor A. Schepetkin, Mark T. Quinn|Biomedicines|2022Cited by 12